The DrugSorb-ATR™ Antithrombotic Removal system is currently being evaluated for the ability to remove ticagrelor during cardiothoracic surgery and to reduce perioperative bleeding risk in the U.S. double-blind, randomized, controlled STAR-T (“Safe and Timely Antithrombotic Removal – Ticagrelor”) pivotal trial.  The DrugSorb-ATR Antithrombotic removal system is based upon the same polymer technology as CytoSorb and is not yet FDA approved.